Journal: Journal of Extracellular Vesicles

Article Title: Enhancing protective immunity against bacterial infection via coating nano‐ Rehmannia glutinosa polysaccharide with outer membrane vesicles

doi: 10.1002/jev2.12514

Figure Lengend Snippet: pRL‐OMV induced DC maturation in vitro. (a–c) Expression levels of (a) MHC II, (b) CD86 and (c) CD80 in BMDCs treated with pRL‐OMV, RL‐OMV, BL‐OMV, RGP‐OMV, OMV, LPS and medium for 24 h. (d) Quantitative data from the results of flow cytometry. Data are expressed in the form of mean ± SE ( n = 4). ns, not significant; * p < 0.05. (e) Surface topographical changes were documented by SEM after pRL‐OMV treatment. Scale bar, 5 µm.

Article Snippet: FITC‐conjugated anti‐mouse MHC Class II, FITC‐conjugated anti‐mouse CD80, PE‐conjugated anti‐mouse CD86, APC‐conjugated anti‐mouse CD11c, FITC‐conjugated anti‐mouse CD4, PE‐conjugated anti‐mouse CD8a, APC‐conjugated anti‐mouse CD3 and PE/Cy7‐conjugated anti‐mouse CD19 antibodies were all obtained from Multi Sciences (Hangzhou, Zhejiang, China).

Techniques: In Vitro, Expressing, Flow Cytometry

Journal: Journal of Extracellular Vesicles

Article Title: Enhancing protective immunity against bacterial infection via coating nano‐ Rehmannia glutinosa polysaccharide with outer membrane vesicles

doi: 10.1002/jev2.12514

Figure Lengend Snippet: pRL‐OMV increased the enrichment of antigen in inguinal lymph nodes and activated lymph node‐associated DCs. (a) Lymph node accumulation of OMVs labelled with OVA‐Cy5.5 in vivo ( n = 3). The inguinal draining lymph nodes, along with several organs, were collected 24 h after subcutaneous injection with the indicated OMV formulations to examine the accumulation of Cy5.5 fluorescence. (b) After ex vivo imaging, the inguinal lymph nodes were collected, frozen, and sectioned and stained for fluorescent imaging via CSLM. Cell nuclei are shown stained in blue (DAPI). Scale bar, 50 µm. (c) Expression of MHC I, MHC II, CD80 and CD86 on DCs in inguinal lymph nodes 7d following the second immunization ( n = 4). LNs were collected and processed into a single‐cell suspension. Following this, cells were analysed by flow cytometry. (d) Quantitative data derived from the flow cytometry results. Data are expressed in the form of mean ± SE ( n = 4). * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: FITC‐conjugated anti‐mouse MHC Class II, FITC‐conjugated anti‐mouse CD80, PE‐conjugated anti‐mouse CD86, APC‐conjugated anti‐mouse CD11c, FITC‐conjugated anti‐mouse CD4, PE‐conjugated anti‐mouse CD8a, APC‐conjugated anti‐mouse CD3 and PE/Cy7‐conjugated anti‐mouse CD19 antibodies were all obtained from Multi Sciences (Hangzhou, Zhejiang, China).

Techniques: In Vivo, Injection, Fluorescence, Ex Vivo, Imaging, Staining, Expressing, Suspension, Flow Cytometry, Derivative Assay

Journal:

Article Title: Toxoplasma gondii regulates recruitment and migration of human dendritic cells via different soluble secreted factors

doi: 10.1111/j.1365-2249.2005.02856.x

Figure Lengend Snippet: Phenotype of DC after 7 days of culture in vitro before contact with T. gondii

Article Snippet: Cells (1·5 × 10 5 ) were incubated with 10 µl labelled monoclonal antibodies (MoAb) for 30 min at 4°C: CD1a (IgG2a; Dako, Trappes, France), CD80-FITC (IgG2b k; Diaclone, Besancon, France), CD83-FITC (IgG2 k; Immunotech, Marseille, France), CD86-FITC (IgG1), CD40 (IgG1; Diaclone); CCR6 (IgM; BD Bioscience, Pont de Claix, France), CCR7 (IgG2B; R & D Systems, Minneapolis, MN, USA) and HLA-DR (IgG2a; Beckton Dickinson, Mountain View, CA, USA).

Techniques: In Vitro